Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapy
US-2024335536-A1 · Oct 10, 2024 · US
Generation of natural killer cells and lymphoid tissue inducer-like (LTi-like) NK-22 cells
US9862928B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9862928-B2 |
| Application number | US-201113991370-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 2, 2011 |
| Priority date | Dec 3, 2010 |
| Publication date | Jan 9, 2018 |
| Grant date | Jan 9, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates generally to methods to prepare NK and LTi-like, NK22 cells from HSCs and uses of those cells.
First claim
Opening claim text (preview).
What is claimed is: 1. A method to produce IL-22 expressing Lymphoid Tissue Inducer-Like (LTi-like) NK22 cells comprising a) initially culturing CD34 + cells in the presence of IL-3 and irradiated stroma; b) culturing the cells from a) in the presence of stem cell factor (SCF), FLT-3L, IL-7, IL-15 and irradiated stroma; c) culturing the cells from b) in the presence of IL-1β and IL-23, but in the absence of IL-7, so as to produce IL-22 expressing LTi-like NK22 cells. 2. The method of claim 1 , wherein the CD34 + cells are seeded onto the stromal cell line. 3. The method of claim 1 , wherein the CD34 30 cells are hematopoietic stem cells (HSCs). 4. The method of claim 1 , wherein the CD34 30 cells are isolated from umbilical cord blood. 5. The method of claim 1 , wherein the cells are cultured for about 7 to about 40 days. 6. The method of claim 1 , further comprising culturing the cells of a), b) and/or c) in the presence of hydrocortisone (HDC).
Assignees
Inventors
Classifications
Stem cell factor [SCF], c-kit ligand [KL] · CPC title
Interleukin-7 (IL-7) · CPC title
from blood or immune system cells · CPC title
Flt-3 ligand (CD135L, flk-2 ligand) · CPC title
Interleukin-15 (IL-15) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9862928B2 cover?
- The present invention relates generally to methods to prepare NK and LTi-like, NK22 cells from HSCs and uses of those cells.
- Who is the assignee on this patent?
- Verneris Michael, Miller Jeff, Blazar Bruce, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0646. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 09 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).